

Global Refractory Multiple Myeloma Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G3153D5EBC41EN.html>

Date: July 2024

Pages: 114

Price: US\$ 4,480.00 (Single User License)

ID: G3153D5EBC41EN

Abstracts

The global Refractory Multiple Myeloma market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Refractory Multiple Myeloma demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Refractory Multiple Myeloma, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Refractory Multiple Myeloma that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Refractory Multiple Myeloma total market, 2018-2029, (USD Million)

Global Refractory Multiple Myeloma total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Refractory Multiple Myeloma total market, key domestic companies and share, (USD Million)

Global Refractory Multiple Myeloma revenue by player and market share 2018-2023, (USD Million)

Global Refractory Multiple Myeloma total market by Type, CAGR, 2018-2029, (USD

Million)

Global Refractory Multiple Myeloma total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Refractory Multiple Myeloma market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG and Takeda Pharmaceutical Company Limited, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Refractory Multiple Myeloma market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Refractory Multiple Myeloma Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Refractory Multiple Myeloma Market, Segmentation by Type

Proteasome Inhibitor

Immunomodulators

Anti-CD38 Monoclonal Antibody

Others

Global Refractory Multiple Myeloma Market, Segmentation by Application

Hospital

Specialty Clinic

Others

Companies Profiled:

Bristol Myers Squibb

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Janssen Global Services, LLC

Gilead Sciences, Inc.

Fresenius Kabi

GSK plc.

Novartis AG

Takeda Pharmaceutical Company Limited

Genentech, Inc.

Key Questions Answered

1. How big is the global Refractory Multiple Myeloma market?
2. What is the demand of the global Refractory Multiple Myeloma market?
3. What is the year over year growth of the global Refractory Multiple Myeloma market?
4. What is the total value of the global Refractory Multiple Myeloma market?
5. Who are the major players in the global Refractory Multiple Myeloma market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Refractory Multiple Myeloma Introduction
- 1.2 World Refractory Multiple Myeloma Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Refractory Multiple Myeloma Total Market by Region (by Headquarter Location)
 - 1.3.1 World Refractory Multiple Myeloma Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.3 China Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.4 Europe Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.5 Japan Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.6 South Korea Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.7 ASEAN Refractory Multiple Myeloma Market Size (2018-2029)
 - 1.3.8 India Refractory Multiple Myeloma Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Refractory Multiple Myeloma Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Refractory Multiple Myeloma Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.2 World Refractory Multiple Myeloma Consumption Value by Region
 - 2.2.1 World Refractory Multiple Myeloma Consumption Value by Region (2018-2023)
 - 2.2.2 World Refractory Multiple Myeloma Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.4 China Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.5 Europe Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.6 Japan Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.7 South Korea Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.8 ASEAN Refractory Multiple Myeloma Consumption Value (2018-2029)
- 2.9 India Refractory Multiple Myeloma Consumption Value (2018-2029)

3 WORLD REFRACTORY MULTIPLE MYELOMA COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Refractory Multiple Myeloma Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Refractory Multiple Myeloma Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Refractory Multiple Myeloma in 2022
 - 3.2.3 Global Concentration Ratios (CR8) for Refractory Multiple Myeloma in 2022
- 3.3 Refractory Multiple Myeloma Company Evaluation Quadrant
- 3.4 Refractory Multiple Myeloma Market: Overall Company Footprint Analysis
 - 3.4.1 Refractory Multiple Myeloma Market: Region Footprint
 - 3.4.2 Refractory Multiple Myeloma Market: Company Product Type Footprint
 - 3.4.3 Refractory Multiple Myeloma Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Refractory Multiple Myeloma Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Refractory Multiple Myeloma Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Refractory Multiple Myeloma Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Refractory Multiple Myeloma Consumption Value Comparison
 - 4.2.1 United States VS China: Refractory Multiple Myeloma Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Refractory Multiple Myeloma Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Refractory Multiple Myeloma Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Refractory Multiple Myeloma Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Refractory Multiple Myeloma Revenue, (2018-2023)

4.4 China Based Companies Refractory Multiple Myeloma Revenue and Market Share, 2018-2023

4.4.1 China Based Refractory Multiple Myeloma Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Refractory Multiple Myeloma Revenue, (2018-2023)

4.5 Rest of World Based Refractory Multiple Myeloma Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Refractory Multiple Myeloma Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Refractory Multiple Myeloma Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Refractory Multiple Myeloma Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Proteosome Inhibitor

5.2.2 Immunomodulators

5.2.3 Anti-CD38 Monoclonal Antibody

5.2.4 Others

5.3 Market Segment by Type

5.3.1 World Refractory Multiple Myeloma Market Size by Type (2018-2023)

5.3.2 World Refractory Multiple Myeloma Market Size by Type (2024-2029)

5.3.3 World Refractory Multiple Myeloma Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Refractory Multiple Myeloma Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Hospital

6.2.2 Specialty Clinic

6.2.3 Others

6.3 Market Segment by Application

6.3.1 World Refractory Multiple Myeloma Market Size by Application (2018-2023)

6.3.2 World Refractory Multiple Myeloma Market Size by Application (2024-2029)

6.3.3 World Refractory Multiple Myeloma Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Bristol Myers Squibb

7.1.1 Bristol Myers Squibb Details

7.1.2 Bristol Myers Squibb Major Business

7.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Product and Services

7.1.4 Bristol Myers Squibb Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Bristol Myers Squibb Recent Developments/Updates

7.1.6 Bristol Myers Squibb Competitive Strengths & Weaknesses

7.2 Teva Pharmaceutical Industries Ltd.

7.2.1 Teva Pharmaceutical Industries Ltd. Details

7.2.2 Teva Pharmaceutical Industries Ltd. Major Business

7.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product and Services

7.2.4 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates

7.2.6 Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses

7.3 Pfizer Inc.

7.3.1 Pfizer Inc. Details

7.3.2 Pfizer Inc. Major Business

7.3.3 Pfizer Inc. Refractory Multiple Myeloma Product and Services

7.3.4 Pfizer Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Pfizer Inc. Recent Developments/Updates

7.3.6 Pfizer Inc. Competitive Strengths & Weaknesses

7.4 Janssen Global Services, LLC

7.4.1 Janssen Global Services, LLC Details

7.4.2 Janssen Global Services, LLC Major Business

7.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Product and Services

7.4.4 Janssen Global Services, LLC Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Janssen Global Services, LLC Recent Developments/Updates

7.4.6 Janssen Global Services, LLC Competitive Strengths & Weaknesses

7.5 Gilead Sciences, Inc.

7.5.1 Gilead Sciences, Inc. Details

7.5.2 Gilead Sciences, Inc. Major Business

7.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Product and Services

7.5.4 Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Gilead Sciences, Inc. Recent Developments/Updates

7.5.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses

7.6 Fresenius Kabi

7.6.1 Fresenius Kabi Details

7.6.2 Fresenius Kabi Major Business

7.6.3 Fresenius Kabi Refractory Multiple Myeloma Product and Services

7.6.4 Fresenius Kabi Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 Fresenius Kabi Recent Developments/Updates

7.6.6 Fresenius Kabi Competitive Strengths & Weaknesses

7.7 GSK plc.

7.7.1 GSK plc. Details

7.7.2 GSK plc. Major Business

7.7.3 GSK plc. Refractory Multiple Myeloma Product and Services

7.7.4 GSK plc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 GSK plc. Recent Developments/Updates

7.7.6 GSK plc. Competitive Strengths & Weaknesses

7.8 Novartis AG

7.8.1 Novartis AG Details

7.8.2 Novartis AG Major Business

7.8.3 Novartis AG Refractory Multiple Myeloma Product and Services

7.8.4 Novartis AG Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 Novartis AG Recent Developments/Updates

7.8.6 Novartis AG Competitive Strengths & Weaknesses

7.9 Takeda Pharmaceutical Company Limited

7.9.1 Takeda Pharmaceutical Company Limited Details

7.9.2 Takeda Pharmaceutical Company Limited Major Business

7.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product and Services

7.9.4 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

- 7.9.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
- 7.9.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
- 7.10 Genentech, Inc.
 - 7.10.1 Genentech, Inc. Details
 - 7.10.2 Genentech, Inc. Major Business
 - 7.10.3 Genentech, Inc. Refractory Multiple Myeloma Product and Services
 - 7.10.4 Genentech, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 7.10.5 Genentech, Inc. Recent Developments/Updates
 - 7.10.6 Genentech, Inc. Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Refractory Multiple Myeloma Industry Chain
- 8.2 Refractory Multiple Myeloma Upstream Analysis
- 8.3 Refractory Multiple Myeloma Midstream Analysis
- 8.4 Refractory Multiple Myeloma Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Refractory Multiple Myeloma Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Refractory Multiple Myeloma Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Refractory Multiple Myeloma Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Refractory Multiple Myeloma Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Refractory Multiple Myeloma Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Refractory Multiple Myeloma Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Refractory Multiple Myeloma Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Refractory Multiple Myeloma Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Refractory Multiple Myeloma Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Refractory Multiple Myeloma Players in 2022

Table 12. World Refractory Multiple Myeloma Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Refractory Multiple Myeloma Company Evaluation Quadrant

Table 14. Head Office of Key Refractory Multiple Myeloma Player

Table 15. Refractory Multiple Myeloma Market: Company Product Type Footprint

Table 16. Refractory Multiple Myeloma Market: Company Product Application Footprint

Table 17. Refractory Multiple Myeloma Mergers & Acquisitions Activity

Table 18. United States VS China Refractory Multiple Myeloma Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Refractory Multiple Myeloma Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Refractory Multiple Myeloma Companies, Headquarters (States, Country)

Table 21. United States Based Companies Refractory Multiple Myeloma Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Refractory Multiple Myeloma Revenue Market Share (2018-2023)

Table 23. China Based Refractory Multiple Myeloma Companies, Headquarters (Province, Country)

Table 24. China Based Companies Refractory Multiple Myeloma Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Refractory Multiple Myeloma Revenue Market Share (2018-2023)

Table 26. Rest of World Based Refractory Multiple Myeloma Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Refractory Multiple Myeloma Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Refractory Multiple Myeloma Revenue Market Share (2018-2023)

Table 29. World Refractory Multiple Myeloma Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Refractory Multiple Myeloma Market Size by Type (2018-2023) & (USD Million)

Table 31. World Refractory Multiple Myeloma Market Size by Type (2024-2029) & (USD Million)

Table 32. World Refractory Multiple Myeloma Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Refractory Multiple Myeloma Market Size by Application (2018-2023) & (USD Million)

Table 34. World Refractory Multiple Myeloma Market Size by Application (2024-2029) & (USD Million)

Table 35. Bristol Myers Squibb Basic Information, Area Served and Competitors

Table 36. Bristol Myers Squibb Major Business

Table 37. Bristol Myers Squibb Refractory Multiple Myeloma Product and Services

Table 38. Bristol Myers Squibb Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Bristol Myers Squibb Recent Developments/Updates

Table 40. Bristol Myers Squibb Competitive Strengths & Weaknesses

Table 41. Teva Pharmaceutical Industries Ltd. Basic Information, Area Served and Competitors

Table 42. Teva Pharmaceutical Industries Ltd. Major Business

Table 43. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product and Services

Table 44. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue,

Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates

Table 46. Teva Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses

Table 47. Pfizer Inc. Basic Information, Area Served and Competitors

Table 48. Pfizer Inc. Major Business

Table 49. Pfizer Inc. Refractory Multiple Myeloma Product and Services

Table 50. Pfizer Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Pfizer Inc. Recent Developments/Updates

Table 52. Pfizer Inc. Competitive Strengths & Weaknesses

Table 53. Janssen Global Services, LLC Basic Information, Area Served and Competitors

Table 54. Janssen Global Services, LLC Major Business

Table 55. Janssen Global Services, LLC Refractory Multiple Myeloma Product and Services

Table 56. Janssen Global Services, LLC Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Janssen Global Services, LLC Recent Developments/Updates

Table 58. Janssen Global Services, LLC Competitive Strengths & Weaknesses

Table 59. Gilead Sciences, Inc. Basic Information, Area Served and Competitors

Table 60. Gilead Sciences, Inc. Major Business

Table 61. Gilead Sciences, Inc. Refractory Multiple Myeloma Product and Services

Table 62. Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Gilead Sciences, Inc. Recent Developments/Updates

Table 64. Gilead Sciences, Inc. Competitive Strengths & Weaknesses

Table 65. Fresenius Kabi Basic Information, Area Served and Competitors

Table 66. Fresenius Kabi Major Business

Table 67. Fresenius Kabi Refractory Multiple Myeloma Product and Services

Table 68. Fresenius Kabi Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Fresenius Kabi Recent Developments/Updates

Table 70. Fresenius Kabi Competitive Strengths & Weaknesses

Table 71. GSK plc. Basic Information, Area Served and Competitors

Table 72. GSK plc. Major Business

Table 73. GSK plc. Refractory Multiple Myeloma Product and Services

Table 74. GSK plc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. GSK plc. Recent Developments/Updates

- Table 76. GSK plc. Competitive Strengths & Weaknesses
- Table 77. Novartis AG Basic Information, Area Served and Competitors
- Table 78. Novartis AG Major Business
- Table 79. Novartis AG Refractory Multiple Myeloma Product and Services
- Table 80. Novartis AG Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Novartis AG Recent Developments/Updates
- Table 82. Novartis AG Competitive Strengths & Weaknesses
- Table 83. Takeda Pharmaceutical Company Limited Basic Information, Area Served and Competitors
- Table 84. Takeda Pharmaceutical Company Limited Major Business
- Table 85. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product and Services
- Table 86. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Takeda Pharmaceutical Company Limited Recent Developments/Updates
- Table 88. Genentech, Inc. Basic Information, Area Served and Competitors
- Table 89. Genentech, Inc. Major Business
- Table 90. Genentech, Inc. Refractory Multiple Myeloma Product and Services
- Table 91. Genentech, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 92. Global Key Players of Refractory Multiple Myeloma Upstream (Raw Materials)
- Table 93. Refractory Multiple Myeloma Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Refractory Multiple Myeloma Picture

Figure 2. World Refractory Multiple Myeloma Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Refractory Multiple Myeloma Total Market Size (2018-2029) & (USD Million)

Figure 4. World Refractory Multiple Myeloma Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Refractory Multiple Myeloma Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Refractory Multiple Myeloma Revenue (2018-2029) & (USD Million)

Figure 13. Refractory Multiple Myeloma Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 16. World Refractory Multiple Myeloma Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 18. China Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 23. India Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Refractory Multiple Myeloma by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Refractory Multiple Myeloma Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Refractory Multiple Myeloma Markets in 2022

Figure 27. United States VS China: Refractory Multiple Myeloma Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Refractory Multiple Myeloma Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Refractory Multiple Myeloma Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Refractory Multiple Myeloma Market Size Market Share by Type in 2022

Figure 31. Proteasome Inhibitor

Figure 32. Immunomodulators

Figure 33. Anti-CD38 Monoclonal Antibody

Figure 34. Others

Figure 35. World Refractory Multiple Myeloma Market Size Market Share by Type (2018-2029)

Figure 36. World Refractory Multiple Myeloma Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 37. World Refractory Multiple Myeloma Market Size Market Share by Application in 2022

Figure 38. Hospital

Figure 39. Specialty Clinic

Figure 40. Others

Figure 41. Refractory Multiple Myeloma Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source

I would like to order

Product name: Global Refractory Multiple Myeloma Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G3153D5EBC41EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3153D5EBC41EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970